Case Summary:

“The biosensors that [the client] has developed improve the specificity and accuracy with which food technology is applicable towards detecting and removing harmful substances that lead to these diseases. They also assist in clinical settings, as these biosensors are applicable to patients to detect substances that influence their condition. The massive improvement in diagnostics and screening within the food and medical industries underscores the substantial nature of [the client’s] work.”

“[The client’s] biosensors selectively detect L-lactate, glucose, and alcohol with greater efficiency and a reduced effort while maintaining accurate results. This means that the forensic labs in the United States are capable of harnessing [the client’s] biosensors to more effectively and rapidly analyze the millions of forensic requests that they receive without compromising the validity of their results. The merit of [the client’s] biosensors is made even more clear the significance of forensic sciences within the United States and the financial investment the nation has committed to this industry.”

These are two small passages taken from letters written for the support of a client of ours hailing from Ukraine. Armed with a Ph.D. in microbiology, he was a research assistant Professor in the area. As an expert in the field, his proposed endeavor was to work on developing novel, sensitive, and selective bioanalytical techniques utilizing nanotechnology and recombinant enzymes in order to improve current methods in biotechnological studies for advancements in medicine, food, clinical diagnostics, and forensic sciences.

On the other hand, we found that his research advancing his proposed endeavor is of great importance because it improves upon the applications of nanotechnology and recombinant enzymes in biotechnologies used in a variety of settings, including to tackle issues like environmental contamination and foodborne illnesses. Not only this, but his proposed endeavor also has broad implications for the United States since the novel bioanalytical techniques he is developing using nanotechnology and recombinant enzymes are particularly beneficial to the medical sector in the United States because of the health issues his bioanalytical techniques are capable of detecting.

In his twenty years of experience within his field of expertise he has completed at least 12 reviews to date and his research has resulted in 68 peer-reviewed journal articles (15 of them first-authored), 14 book chapters, and 3 published patents. And these publications have been cited 914 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of biotechnologies.

Furthermore, his study has received funding from INTAS (International Association for the promotion of cooperation with scientists from the independent states of the former Soviet Union) Open Call. The NATO Science for Peace and Security Programme has also supported his study.

So, when his approval came through, we were glad to have been of assistance to him in the approval. We wish him all the best in his future endeavors.